Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause C-reactive protein increased? 414 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 414 reports of C-reactive protein increased have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.5% of all adverse event reports for PEMBROLIZUMAB.

414
Reports of C-reactive protein increased with PEMBROLIZUMAB
0.5%
of all PEMBROLIZUMAB reports
75
Deaths
286
Hospitalizations

How Dangerous Is C-reactive protein increased From PEMBROLIZUMAB?

Of the 414 reports, 75 (18.1%) resulted in death, 286 (69.1%) required hospitalization, and 43 (10.4%) were considered life-threatening.

Is C-reactive protein increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 414 reports have been filed with the FAERS database.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause C-reactive protein increased?

METHOTREXATE (5,999) ADALIMUMAB (4,579) RITUXIMAB (4,060) ETANERCEPT (3,922) TOCILIZUMAB (3,719) INFLIXIMAB (3,621) LEFLUNOMIDE (3,574) HYDROXYCHLOROQUINE (3,552) ABATACEPT (3,451) SULFASALAZINE (3,096)

Which PEMBROLIZUMAB Alternatives Have Lower C-reactive protein increased Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All C-reactive protein increased Reports All Drugs Causing C-reactive protein increased PEMBROLIZUMAB Demographics